The levels of CCT6A, a subunit of the CCT complex, are increased in plasma from patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), in which CCT6A may represent an autoantigen recognizable by γδ T cells [103]. This evidence concerns the gene FLVCR2 and autoimmune disease.